Figure 4.
(A) Mean exogenous factor (F)IX consumption (IU/y) during the lead-in period compared with years 1 to 4 postetranacogene dezaparvovec treatment, and (B) relative contribution of participants to mean FIX consumption (IU/y) over 4 years posttreatment. AAV5, adeno-associated viral vector serotype 5; NAb, neutralizing antibody; NAb+, with preexisting AAV5 NAbs at baseline.
